Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results
Nyxoah SA - Ordinary Shares (NYXH)
Company Research
Source: GlobeNewswire
REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating ResultsFDA PMA Application Review Nearing ConclusionPositioned for U.S. Commercial Launch in March 2025 Mont-Saint-Guibert, Belgium – March 13, 2024, 7:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the fourth quarter and financial year 2024. Recent Financial and Operating Highlights Revenue for the fourth quarter of 2024 was €1.3 million, which excludes €0.6 million of deferred revenueRevenue for the full year 2024 was €4.5 million, which excludes €0.6 million of deferred revenueGross margin for the fourth quarter of 2024 was 73%At December 31, 2024, cash and financial assets were €85.6 million, compared to €57.7 million at December 31, 2023Assembled U.S. executive leadershi
Show less
Read more
Impact Snapshot
Event Time:
NYXH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NYXH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NYXH alerts
High impacting Nyxoah SA - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NYXH
News
- Nyxoah Announces Issuance of First Tranche of Convertible BondsGlobeNewswire
- Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the NetherlandsGlobeNewswire
- Publication relating to transparency notificationsGlobeNewswire
- Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS RuleGlobeNewswire
NYXH
Earnings
- 11/13/25 - Miss
NYXH
Sec Filings
- 12/19/25 - Form 6-K
- 12/5/25 - Form 6-K
- 11/24/25 - Form SCHEDULE
- NYXH's page on the SEC website